Brazilian guidelines on hematopoietic stem cell transplantation in acute myeloid leukemia. (11th October 2016)

• Record Type: Journal Article
• Authors: Silla, Lucia; Dulley, Frederico; Saboya, Rosaura; Kerbauy, Fabio; de Moraes Arantes, Adriano; Pezzi, Annelise; Gross, Luisa Grave; Paton, Eduardo; Hamerschlak, Nelson
• Is Part Of: European journal of haematology. Volume 98:Number 2(2017:Feb.)
• Page Start: 177
• Page End: 183
• Publication Date: 2016-10-11
• Subjects: acute myeloid leukemia -- guideline -- bone marrow transplantation -- hematopoietic stem cell transplantation; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.12808
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Introduction/Objectives: Acute myeloid leukemia (AML) accounts for 90% of all cases of acute leukemia in adults. In Brazil, the mortality from myeloid leukemia is 1.74/100 000 men and 1.37/100 000 women. Our aim was to review and update guidelines of the Brazilian Society of Bone Marrow Transplantation on indications of hematopoietic stem cell transplantation (HSCT) for the treatment AML. Conclusions: (i) Allo‐HSCT is recommended for high‐risk AML (IA); (ii) allo‐HSCT is recommended for AML of intermediate risk (IA); (iii) allo‐HSCT is recommended for AML relapsed/refractory (C4); (iv) auto‐HSCT is recommended for AML after 1 consolidation (C4); (v) auto‐HSCT is recommended for AML in CR1 (higher than QT in the Brazilian experience) (C4); (vi) auto‐HSCT is accepted for AML M3 in second molecular complete remission (2B); (vii) peripheral blood instead of Bone Marrow HSC for advanced disease (2A); (viii) recommended conditioning protocols: Bu‐Cy/Bu‐Mel, Bu‐Flu, TBI‐Cy. In umbilical cord HSCT, consider ATG‐based protocols (2A); (ix) allogeneic HSCT for the treatment of AML can be used in patients between 60 and 80 yr with good performance status and the absence of significant comorbidities (C4).